Kornimate/medical-research-clean huggingface dataset:
relation between acute kidney injury and mineral bone disease

Conditions: Acute Kidney Injury

Summary: relation between acute kidney injury and mineral bone disease

assiut medical school research proposal form 2 part 2: research details 2.1 background (research question, available data from the literature, current strategy for dealing with the problem, rationale of the research that paves the way to the aim(s) of the work). numerous studies have evaluated the prevalence and importance of mineral and bone disorders among patients with chronic kidney disease (ckd) and end-stage renal disease (esrd). however, little is known about dysregulated mineral and bone metabolism in acute kidney injury (aki) \[ acute kidney injury is the new consensus term for acute renal failure it refers to a clinical syndrome characterised by a rapid (hours to days) decrease in renal excretory function, with the accumulation of products of nitrogen metabolism such as creatinine and urea and other clinically unmeasured waste products. other common clinical and laboratory manifestations include decreased urine output (not always present), accumulation of metabolic acids, and increased potassium and phosphate concentrations. the term acute kidney injury has replaced acute renal failure to emphasise that a continuum of kidney injury exists that begins long before sufficient loss of excretory kidney function can be measured with standard laboratory tests. the term also suggests a continuum of prognosis, with increasing mortality associated with even small rises in serum creatinine, and additional increases in mortality as creatinine concentration rises. the incidence of acute kidney injury (aki) is increasing among hospitalized patients . treating the condition consumes significant amounts of resources even after hospital discharge . although aki was once considered a reversible condition, mounting evidence has indicated that aki may have a negative impact upon subsequent renal function and long-term prognosis, even if kidney

Eligibility criteria:
inclusion criteria: * 200 patients with acute kidney injury and their relationship to mineral bone disease. exclusion criteria: * non hypertensive * non cardiac * active malignancy * acute or chronic liver disease * acute poisoning * covid
z-360 in unresectable advanced pancreatic cancer in combination with gemcitabine treatment

Conditions: Pancreatic Cancer

Summary: to evaluate the safety of two doses of z-360 with gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for phaseii study


Eligibility criteria:
inclusion criteria: * subjects with unresectable locally advanced or metastatic pancreatic cancer * kps \> 70% * life expectancy of at least 3 months exclusion criteria: * received previous chemotherapy for the current indication * received previous radiotherapy for the current indication * currently receiving chemotherapy
detection of annexin a2 in systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus (SLE); Lupus Nephritis

Summary: there is substantial clinical and biological intra and inter-patient variability in sle. vascular, renal and neurologic deficiency can be organ-threatening or even life-threatening, leading to increased morbidity and mortality. thus, biomarkers of disease activity and prognosis are required for regular follow-up of sle patients. implication of toll-like receptors (tlrs) in sle has been extensively studied in mice models and humans. self nuclear antigens bind to tlrs which are located on the surface of dendritic cells, b-cells, and endothelial cells, leading to production of pro-inflammatory cytokines and pathologic autoantibodies involved in organ dysfunction of sle patients. moreover, tlr expression in sle is significantly higher and significantly correlated with disease activity. annexin a2 (anxa2) is a member of the annexins superfamily which exists as a monomer or heterotetramer and is implicated in several biological processes. most notably, it binds to ß2gp1/anti-ß2gp1 antibodies and mediates endothelial cell activation via a tlr4 signaling pathway, highlighting its key role in antiphospholipid syndrome (aps) frequently associated with sle. anxa2 is also involved in the physiopathology of sle. anti-dna autoantibodies can bind with anxa2 expressed on mesangial cells in lupus nephritis. besides, a french study carried out in amiens' university hospital showed that vascular lesions in lupus nephritis were associated with a significant increase in vascular expression of anxa2.


Eligibility criteria:
inclusion criteria: inclusion criteria for patients : * age ≥ 18 years old * all sle patients fulfilling the 1997 acr criteria, followed at the departments of internal medicine and nephrology at chu amiens-picardie, regardless of clinical status, treatment, and disease activity. * written informed consent inclusion criteria for control subjects : * age ≥ 18 years old * written informed consent the patients will be compared with age- and sex-matched control subjects. exclusion criteria: * drug-induced lupus erythematosus * refusal or incapacity to provide a written informed consent

Keywords: annexin a2 biomarker
comparing biofinity toric multifocal to ultra multifocal for astigmatism

Conditions: Astigmatism; Presbyopia

Summary: the objective of the study was to compare the handling and performance of biofinity toric multifocal to ultra multifocal for astigmatism.

the objective of the study was to compare the handling and performance of biofinity toric multifocal to ultra multifocal for astigmatism. this is a prospective, randomized, participant masked, crossover, bilateral dispensing study.

Eligibility criteria:
inclusion criteria: 1. is at least 42 years of age and has full legal capacity to volunteer; 2. has read and signed an information consent letter; 3. self reports having a full eye examination in the previous two years; 4. anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week; 5. is willing and able to follow instructions and maintain the appointment schedule; 6. habitually wears soft contact lens for the past 3 months minimum; 7. has refractive astigmatism of at least -0.75dc; 8. is presbyopic and requires a reading addition of at least +0.75d; 9. can be fit and achieve binocular distance vision of at least 20/30 snellen (or +0.20 logmar) which participants also deem to be 'acceptable', with the available study lens parameters (sphere +4 to -6; cylinder -0.75 to -1.75dc; near addition +0.75 to +2.50). exclusion criteria: 1. is participating in any concurrent clinical or research study; 2. habitually wears one of the study contact lenses; 3. has any known active\* ocular disease and/or infection; 4. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 5. is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable; 6. has known sensitivity to the diagnostic sodium fluorescein and/or the care product opti-free puremoist being used in the study; 7. self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment; 8. has undergone refractive error surgery. \* for the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
study evaluating tti-237 in advanced malignant solid tumors.

Conditions: Tumors; Neoplasms

Summary: the purpose of this study is to evaluate the safety, tolerability, and mtd (maximum tolerated dose) of tti-237 for the treatment of subjects with advanced malignant solid tumors.


Eligibility criteria:
inclusion criteria: * documented diagnosis of malignant solid tumor with measurable disease * life expectancy of at least 12 weeks * ecog (the eastern cooperative oncology group scale) performance status of 0, 1, or 2 exclusion criteria: * recent major surgery, radiation therapy or anti-cancer treatment * history of any other prior malignancy within the last 5 years

Keywords: advanced malignant solid tumors
fosmidomycin and azithromycin for acute uncomplicated plasmodium falciparum malaria (p. malaria) in adults

Conditions: Malaria

Summary: the aim of this study is to evaluate the role of azithromycin as a possible combination partner for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute plasmodium falciparum malaria while retaining its excellent safety profile.

the scientific rationale for the use of this combination is to inhibit the ability of the parasite to synthesise isoprenoids, as precursors of many essential compounds including sterols, carotenoids and ubiquinones. this is effected through blockade of the non-mevalonate pathway by fosmidomycin as a potent inhibitor of 1-deoxy-d-xylulose 5-phosphate reductoisomerase coupled with targeting of protein biosynthesis by azithromycin through binding to the 50s ribosomal subunit. this mode of action contrasts with the ability of the human host to utilise the mevalonate pathway for isoprenoid synthesis and accounts for the safety profiles of both drugs through the mechanism of selective toxicity. moreover it affords protection against cross resistance with existing chemotherapeutic agents. the dose of fosmidomycin, equivalent to 30mg/kg twice daily for three days, selected for evaluation in this proof of concept study is derived from the highest dose that was administered in the phase i safety tolerance studies. while the recommended dose of azithromycin for the treatment of bacterial infections is 250mg daily for three days, higher doses of up to 1500mg daily for three days have been evaluated for the treatment of malaria, in combination with artesunate or quinine.

Eligibility criteria:
inclusion criteria: * male and female subjects aged 15 to 55 years * body mass index ≥ 18.5kg/m2 * uncomplicated p falciparum malaria with acute manifestations * asexual parasitaemia between 500ul and 100,000ul * ability to tolerate oral therapy * able to give informed signed consent exclusion criteria: * signs of severe malaria, according to who criteria * body mass index ≤ 18.5 kg/m2 * pregnancy by history or by positive urine test * lactation * mixed plasmodial infection * concomitant disease masking assessment of response, including diabetes, uncontrolled hypertension, heart failure, hepatic dysfunction (alanine-amino transferase \> 150 u/l), renal impairment (creatinine \> 125 umol/l or 3 mg/dl), haemoglobin \ 12000/ul * anti-malarial treatment within previous 28 days * symptomatic aids

Keywords: malaria plasmodium falciparum acute uncomplicated
evaluation of the efficacy and safety of insulin detemir compared with that of nph insulin in subjects with type 1 diabetes.

Conditions: Diabetes Mellitus, Type 1

Summary: the aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/ml formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent obtained before any trial-related activities * type 1 diabetes diagnosed and classified according to aetiology * duration of type 1 diabetes equal to or more than 12 months * glycosylated haemoglobin less than or equal to 12 percent based on analysis from central laboratory * able and willing to perform self-blood glucose monitoring exclusion criteria: * proliferative retinopathy * total basal insulin dose of more than 100 iu per day * recurrent major hypoglycaemia - that would interfere with trial participation (as judged by the investigator) * known unawareness of hypoglycaemia * previous treatment with insulin detemir
the effect of a nutritional supplement on post prandial glucose and lipids in an adult population

Conditions: Impaired Fasting Glucose

Summary: the primary aim of this study is to evaluate the effect of a fibre rich health food drink on the post prandial glucose and triglyceride peak in healthy overweight adults with impaired fasting glucose (ifg). the study is randomised, stratified, double blind, two treatments, two period cross over study.


Eligibility criteria:
inclusion criteria: * healthy overweight male and female participants * age 18-75 years * bmi ≥25\<35 kg/m2 exclusion criteria: * pregnancy/breast-feeding * allergy/intolerance * anaemic participants: hb \<10g/dl * diabetic participants: fasting blood glucose \>125 mg/dl * serum aspartate transaminase, alkaline phosphatase and serum albumin level 3 times the upper limit of normal range * participants on other medications (lipid lowering drugs, oral hypoglycemics)

Keywords: fibre overweight impaired fasting glucose
circulating fibrocytes in non-small cell lung cancer.

Conditions: NSCLC

Summary: the investigators will collect fibrocytes (cd45+col-1+) in patients with non-small cell lung cancer (nsclc). the investigators hypothesize that patients with nsclc experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in nsclc patients.

fibrocytes have been described in both mice and humans, where they bear a hematopoietic progenitor phenotype (cd45+col-1+). fibrocytes have previously been described in murine cancer, implicated as mediators of tumor immune escape. in this study, the investigators will collect fibrocytes including cd45+col-1+ expression. the cells express indoleamine oxidase, which is primarily responsible for their immunosuppressive properties. the investigators hypothesize that patients with non-small cell lung cancer experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in non-small cell lung cancer patients.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed non-small cell lung cancer (nsclc). exclusion criteria: * combination of other malignancy. * age less than 20 years (not include 20 years). * pregnancy.

Keywords: circulating fibrocytes fibrocyte nsclc treatment response survival stage
covid-19 impact on the lombardy region's emergency system

Conditions: Covid19

Summary: this study has 3 main goals: * to quantitavely describe the covid-19 impact on the organization and functioning of the lombardy's emergency system; * to create statistical model able to predict the flow of patients to the emergency room during the epidemic period and their destination (ex: discharge, hospitalization, death); * to value the impact on the non covid-19 patients, both for their possibility to receive medical treatment and as an outcome on their health

the aim of this study is to evaluate the impact that covid-19 had on the emergency system of lombardy. for instance, it affected the job organization and the possibility of responding to general health needs. first of all, the study will consider the calls to the emergency medical service, the number of accesses to the emergency department, the waiting time before hospitalization, the ed output home (discharge, hospitalization, death, self-discharge before the end of the visit). secondly, a statistical model will be implemented, in order to predict the number of patients in need of hospitalization for each day during the pandemic period. this model could help the re-organization of the hospital itself in case of a new covid-19 outbreak. finally, it will evaluate the impact on non-covid patients, to see the difference in the mortality trends and their possiblity to be cured in a proper way.

Eligibility criteria:
inclusion criteria: * over 18y exclusion criteria: * none

Keywords: emergency department emergency medical services
rna sequencing of solid and cystic lesions of the pancreas

Conditions: Pancreas Cyst; Pancreas Mass

Summary: the nature of cysts and solid masses in the pancreas can be difficult to diagnose. they may be benign, precancerous, or cancer. current tests such as cytology (looking under a microscope) and tumor markers do not always give us the answer. the investigators are looking for genetic markers on biopsy specimens from the pancreas that will give us a better test for diagnosis. this study is only for diagnosing these lesions. the investigators are not treating any patients.


Eligibility criteria:
inclusion criteria: * greater than 18 years old, * not pregnant, * referred for endoscopic ultrasound, * have a cyst or mass of the pancreas needing diagnosis. exclusion criteria: * pregnant, * less than age 18, * no mass or cyst found.
study to determine safety and effectiveness of tadalafil on prostate related sex organ/urinary tract problems

Conditions: Prostatic Hyperplasia; Prostate

Summary: study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.


Eligibility criteria:
inclusion criteria: * 6 month history of lower urinary tract symptoms either obstructive and/or irritative secondary to prostate related problems as diagnosed by a urologist. * stopped using treatments at least four weeks prior to study and agree to not use any other treatments during the study. * meet required prostate symptom score and urine flow rate. exclusion criteria: * serum prostate specific antigen (psa) greater than 10 (between 4 and 10, inclusive, without a negative biopsy w/in the last 6 months. * prostate removal and various other pelvic surgeries. * neurological disease or condition known to affect the bladder. * clinical evidence of prostate cancer, urinary tract inflammation or infection, including prostatitis. * have taken medications such as nitrates, finasteride, or dutasteride within the year.
comparison of ultrasound-guided brachial plexus blocks and selective distal blocks in terms of anesthesia

Conditions: Pain, Postoperative; Anesthesia, Local; Patient Satisfaction

Summary: ultrasound-guided brachial plexus blocks (infraclavicular, axillary) can be applied as the main anesthetic method in hand and wrist surgeries, as well as single or combination block applications of the median, radial and ulnar nerves at the forearm level. here, we aimed to retrospectively evaluate the perioperative and postoperative data of patients who underwent hand and wrist surgery under distal nerve blocks and brachial plexus blocks in our hospital.

the retrospective files of patients who used ultrasound guided regional anesthesia techniques as the main anesthetic method in hand and wrist surgeries in our hospital between 01.01.2021 and 01.09.2022 will be examined. patients over the age of 18 who go to hand and wrist surgery will be included. patients who have undergone surgical intervention in more than one region in the same session and who have psychiatric disorders that will affect the perception of pain will be excluded from the study. demographic characteristics, american society of anesthesiology (asa) scores, comorbidity, block performed (distal peripheral nerve block and/or brachial nerve block) and volume applied, block performance time, first analgesia times, surgery times, surgery types, discharge times, additional the existence of the complaint will be recorded. the data obtained by grouping the patients according to the type of anesthesia applied (brachial plexus block and distal nerve blocks) will be subjected to statistical analysis.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 who go to hand and wrist surgery will be included. exclusion criteria: * patients who have undergone surgical intervention in more than one region in the same session and who have psychiatric disorders that will affect the perception of pain will be excluded from the study.

Keywords: distal nerve block,patient satisfaction,hand surgery
liquid nutritional supplement on malnutrition hospitalized patient

Conditions: Malnutrition

Summary: the aim of this study is to know the effectivity of liquid nutritional supplementation in malnutrition hospitalized patients


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old to 60 years old * malnutrition hospitalized patient based on european society for clinical nutrition and metabolism (espen) 2015 criteria * agreed to participate exclusion criteria: * malignancy * chronic kidney disease stage iii-v * decompensated hepatic cirrhosis * allergic to milk or lactose intolerance * could not be randomised and participate in this study by clinical judgement

Keywords: liquid nutritional supplement
pep005 gel - evaluation of local tolerability after exposure to ingenol mebutate gel followed by hand washing in healthy subjects

Conditions: Healthy; Actinic Keratosis

Summary: the purpose of this phase 1 trial is to investigate the local tolerability on the finger following exposure to pep005 gel 0.015% or 0.05% and hand washing once daily, for 2 or 3 consecutive days.


Eligibility criteria:
inclusion criteria: * must be male or female and at least 18 years of age * female patients must be of: non-childbearing potential or if of childbearing potential then have a negative serum and urine pregnancy test and using effective contraception * ability to provide informed consent exclusion criteria: * have received treatment with immunomodulators, or interferon/interferon inducers or systematic medications that suppress the immune system in the last 4 weeks * exposed to prescribed systemic (take as tablet, injection etc) or topical (gel, cream, lotion) medication within the last 7 days * have any signs of skin irritation or damaged skin at or around the dominant index finger * have worked in an occupation with a high risk of being in contact with irritative material (eg. chemicals, painting) on their hands, especially fingers * those who are currently participating in any other clinical trial * those known or suspected of not being able to comply with the requirements of the protocol * females who are pregnant or are breastfeeding